pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

732 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1880Endpoints1458Fierce Biotech773BioSpace762BioPharma Dive551raps253onclive165fda recalls
therapy area
allOncology12979Rare Disease3371Immunology3063Cardiology2861Hematology2315Pulmonology2256Vaccines
  • Novartis CEO says AI could cut drug development time and boost success rates
    At an investor event in London, Novartis chief executive Vas Narasimhan, who also sits on the board of AI company Anthropic, explained how the Swiss drugmaker is turning to artificial intelligence…
    Fierce Biotech · 16h agoPositive↗ source
  • Isomorphic Labs partners with Merck on AI-driven oncology drug discovery after $5 billion funding round
    Isomorphic Labs announced a new collaboration with Merck & Co., adding the pharma giant to its AI drug discovery partners. The agreement follows Isomorphic's recent $5 billion financing and will f…
    Fierce Biotech · 1d agoDealPositive↗ source
← prev
page 1 of 30
next →
122
fda medwatch116
globenewswire health73
fda press62
1881
Psychiatry & CNS1235
Ophthalmology1140
Endocrinology & Metabolism809
Pain793
Nephrology788
  • AbbVie partners with Disco Pharmaceuticals on up to $2.5 billion solid tumor deal
    AbbVie announced a partnership with Disco Pharmaceuticals, a preclinical cancer biotech based in Cologne, Germany, to advance antibody‑drug conjugate and T cell engager programs targeting solid tum…
    Endpoints · 1d agoDealPositive↗ source
  • Evaxion Biotech Shifts R&D Focus Exclusively to Cancer Vaccines, Halts Infectious and Autoimmune Programs
    Evaxion Biotech announced it is ending its infectious disease and autoimmune research programs to concentrate solely on oncology. The company’s most advanced candidate is EVX-01, a therapeutic can…
    Fierce Biotech · 23h agoNeutral↗ source
  • Pfizer signs $2.6 billion deal with China's Starna to acquire in vivo CAR-T programs for autoimmune diseases
    Pfizer announced a $2.6 billion agreement with Chinese biotech Starna Therapeutics to obtain rights to three preclinical in vivo CAR-T candidates aimed at autoimmune diseases. The deal includes a…
    Fierce Biotech · 2d agoDealPositive↗ source
  • AbbVie inks up to $2.5 billion deal with Disco to pursue bispecific cancer therapeutics
    AbbVie announced a collaboration with German biotech Disco Pharmaceuticals that could be worth up to $2.5 billion. The agreement provides a $40 million upfront payment, with the balance linked to…
    Fierce Biotech · 1d agoDealPositive↗ source
  • Pfizer licenses three in vivo CAR-T assets from Starna for $330 million to target autoimmune disease outside Greater China
    Pfizer announced a licensing agreement with Starna Therapeutics, a Chinese biotech, to acquire exclusive rights to three pre-IND in vivo CAR-T programs aimed at autoimmune diseases. Under the deal…
    Endpoints · 1d agoDealPositive↗ source
  • Merck halts development of BTK inhibitor acquired in $2.7 billion ArQule purchase
    Merck announced it is stopping work on nemtabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. The drug was the primary asset that motivated Merck’s 2019 acquisition of ArQule for $2.7 billion.…
    Endpoints · 1d agoDealNegative↗ source
  • Merck halts $2.7 billion BTK inhibitor program after negative phase 3 data
    Merck announced it is discontinuing its BTK inhibitor nemtabrutinib program, ending three phase 3 trials in chronic lymphocytic leukemia and small lymphocytic lymphoma. The decision follows a reco…
    Fierce Biotech · 2d agoNegative readoutNegative↗ source
  • Big Pharma execs urge biotech firms to be transparent and patient to win deals
    At Fierce Biotech's London Life Sciences Week, representatives from five major pharmaceutical companies shared how they evaluate biotech partners. Bayer's head of business development warned that…
    Fierce Biotech · 2d agoDealNeutral↗ source
  • Crown Biosciences remains independent after $204 million Adicon acquisition collapses
    Crown Biosciences, a contract research organization, will continue operating on its own after a planned sale to China's Adicon did not close. The parties announced on Nov 16 that they were ending…
    Fierce Biotech · 1d agoDealNegative↗ source
  • Roche secures FDA approval for giredestrant, its first SERD for advanced breast cancer
    Roche announced that its experimental breast cancer drug giredestrant received FDA approval for treatment of patients with late‑stage disease. The approval places Roche into the selective estrogen…
    Endpoints · 2d agoApprovalPositive↗ source
  • Isomorphic Labs secures $5 billion Series C, doubling its recent $2.1 billion raise
    Isomorphic Labs, an AI‑driven drug discovery startup spun out of DeepMind, announced a $5 billion Series C financing, marking its second multibillion‑dollar round within six months. The funding fo…
    Fierce Biotech · 3d agoDealPositive↗ source
  • Eli Lilly inks $5.9 billion partnership with Stipple Bio to develop precision oncology drugs
    Eli Lilly has announced a partnership with Stipple Bio that could be worth up to $5.9 billion. The collaboration will focus on oncology drug candidates designed to target tumor cells more precisely…
    Fierce Biotech · 3d agoDealPositive↗ source
  • GSK receives accelerated FDA approval for oral lung cancer drug neladalkib
    GSK announced that the U.S. Food and Drug Administration granted accelerated approval to its oral lung cancer therapy neladalkib. The approval comes as part of the company's $10.6 billion acquisit…
    Endpoints · 2d agoApprovalPositive↗ source
  • Sellas Life Sciences reports Phase 3 success for AML vaccine galinpepimut-S
    Sellas Life Sciences announced on Tuesday that its experimental cancer vaccine achieved a positive outcome in a Phase 3 study. The trial enrolled patients with a specific form of acute myeloid leu…
    Endpoints · 2d agoPositive readoutPositive↗ source
  • FDA rejects Summit’s ivonescimab, citing China‑centric data and missed survival benefit
    The FDA sent Summit Therapeutics a complete response letter on Nov 13, rejecting its PD‑1×VEGF bispecific antibody ivonescimab. Reviewers said the pivotal HARMONi trial was dominated by patients f…
    Fierce Biotech · 2d agoCRLNegative↗ source
  • FDA flags VEGF safety concern in Summit Therapeutics' rejected bispecific cancer drug ivonescimab
    The U.S. Food and Drug Administration identified a potential safety issue while reviewing ivonescimab, a bispecific cancer therapy being developed by Summit Therapeutics and Akeso. The agency’s co…
    Endpoints · 2d agoRegulatoryNegative↗ source
  • Kyntra Bio drops mid-stage prostate cancer ADC program after failing efficacy criteria
    Kyntra Bio announced in its third-quarter earnings release that it is terminating the phase 2 study of its CD46-targeting antibody-drug conjugate FG-3246 in metastatic castration-resistant prostate…
    Fierce Biotech · 2d agoNegative↗ source
  • Recon: FDA approves Roche’s oral SERD for late-stage breast cancer; Lilly strikes up to $5.9B cancer deal with Stipple Bio
    Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
    raps · 3d ago↗ source
  • Eli Lilly inks up to $5.9 billion partnership with Stipple Bio to develop cancer therapies
    Eli Lilly announced a new collaboration with Cambridge-based biotech Stipple Bio, valued at up to $5.9 billion, aimed at creating novel cancer medicines. The agreement gives Lilly access to Stippl…
    Endpoints · 3d agoDealPositive↗ source
  • Biogen signs $411 million deal with TrimTech to develop protein degraders for neurodegenerative diseases
    Biogen announced a collaboration with UK‑based TrimTech Therapeutics, valued at up to $411 million in biobucks, to create small‑molecule protein degraders aimed at neurodegenerative disorders. The…
    Fierce Biotech · 3d agoDealPositive↗ source
  • AriBio’s oral Alzheimer’s candidate shows significant benefit in monotherapy subgroup in phase 3 trial
    AriBio’s AR1001, an oral PDE5 inhibitor originally developed for erectile dysfunction, is being tested as a treatment for early Alzheimer’s disease. In the global phase 3 Polaris-AD trial, the dru…
    Fierce Biotech · 3d agoPositive readoutNeutral↗ source
  • Sellas vaccine shows 9-month overall survival gain in phase 3 AML trial
    Sellas Life Sciences reported results of a phase 3 trial of its peptide vaccine galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML). The study met its primary endpoint, showing a me…
    Fierce Biotech · 3d agoPositive readoutPositive↗ source
  • CG Oncology reports 68% drop in bladder cancer recurrence in phase 3 trial of cretostimogene
    CG Oncology announced results from a phase 3 study of its oncolytic virus immunotherapy, cretostimogene, in patients with non-muscle invasive bladder cancer after surgery. The trial, involving 367…
    Fierce Biotech · 3d agoPositive readoutPositive↗ source